Eric Johnson, PhD
Southeast Field Application Scientist Manager
Bio-Rad
Geoff Bien
Director, Product Market Development
Insight Molecular Diagnotics
Ekkehard Schuetz, MD, PhD, FAACC
Chief Science Officer
Insight Molecular Diagnotics
Ryan Andrews
VP Commercial
Insight Molecular Diagnotics
Donor-derived cell-free DNA (dd-cfDNA) has demonstrated strong diagnostic and clinical utility in transplant rejection monitoring. As applications continue to expand into longitudinal surveillance and therapeutic response monitoring, the need for rapid, decentralized access to results is increasing. Technologies like digital PCR (dPCR) empower researchers to develop assays with lower detection limits, direct quantitation, and results within a single day turnaround, all features which are crucial for decentralizing access to dd-cfDNA testing.
In this session, we introduce GraftAssureIQ™, a ddPCR-based test kit designed for local laboratory implementation, delivering same-day turnaround time and dual quantification of dd-cfDNA (absolute and fractional). Developed on the Bio-Rad QX600 dPCR system and leveraging preselected SNPs of high global minor allele frequency, GraftAssureIQ enables more timely clinical insights and expands access to this critical biomarker beyond centralized reference labs—supporting a future where precision transplant care is both accessible and actionable at the point of need.
Donor-derived cell-free DNA (dd-cfDNA) has demonstrated strong diagnostic and clinical utility in transplant rejection monitoring. As applications continue to expand into longitudinal surveillance and therapeutic response monitoring, the need for rapid, decentralized access to results is increasing. Technologies like digital PCR (dPCR) empower researchers to develop assays with lower detection limits, direct quantitation, and results within a single day turnaround, all features which are crucial for decentralizing access to dd-cfDNA testing.
In this session, we introduce GraftAssureIQ™, a ddPCR-based test kit designed for local laboratory implementation, delivering same-day turnaround time and dual quantification of dd-cfDNA (absolute and fractional). Developed on the Bio-Rad QX600 dPCR system and leveraging preselected SNPs of high global minor allele frequency, GraftAssureIQ enables more timely clinical insights and expands access to this critical biomarker beyond centralized reference labs—supporting a future where precision transplant care is both accessible and actionable at the point of need.